Here’s a bold statement: a single class of drugs could revolutionize the way we treat kidney disease, regardless of how well your kidneys are functioning. But here’s where it gets controversial—should these drugs be prescribed to everyone, even those without diabetes or with advanced kidney issues? Let’s dive into the groundbreaking findings that are shaking up the medical world.
Two massive studies have revealed that sodium-glucose co-transporter 2 (SGLT2) inhibitors—originally designed for type 2 diabetes—offer remarkable protection against kidney disease progression, hospitalizations, and even death. And this isn’t just for people with diabetes; the benefits extend to those without it, too. And this is the part most people miss—these drugs work effectively across all levels of kidney function, even in cases where their use wasn’t previously recommended.
Presented at the American Society of Nephrology Kidney Week and published in JAMA, these findings are based on data from over 70,000 participants across 10 major trials. The research, led by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C) at The George Institute for Global Health, found that SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% compared to a placebo. They also slowed the decline of kidney function by 51%, regardless of the patient’s starting point.
What’s truly groundbreaking is that these benefits were observed even in people with stage 4 CKD—a group often considered too advanced for such treatments. Similarly, individuals with minimal or no protein in their urine (a sign of early kidney disease) also saw significant improvements. This challenges existing treatment guidelines and raises the question: Should we rethink how broadly these drugs are prescribed?
The second analysis focused on hospitalizations and found that SGLT2 inhibitors reduced heart failure admissions by nearly a third in diabetic patients and a quarter in non-diabetic patients. The risk of side effects was minimal, making the health benefits overwhelmingly positive. Associate Professor Brendon Neuen, a lead researcher, emphasized that these findings support simplifying treatment guidelines to encourage wider use of SGLT2 inhibitors.
CKD affects approximately 850 million people globally, with the highest burden in low- and middle-income countries where access to these drugs is limited. As generic versions become more affordable, this presents a rare opportunity to transform kidney care worldwide. But here’s the debate—how do we balance accessibility with the cost and logistics of widespread implementation? And should we prioritize these drugs for those at highest risk, or make them available to everyone?
These studies provide the strongest evidence yet for the universal use of SGLT2 inhibitors in CKD patients. But what do you think? Should these drugs be a standard treatment for all kidney function levels, or are there risks we’re overlooking? Share your thoughts in the comments—let’s spark a conversation that could shape the future of kidney care.
